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Abstract
Background: Many pathogens exist in multiple physiological niches within the host. Differences between aerobic and 
anaerobic conditions are known to alter the expression of bacterial virulence factors, typically through the conditional 
activity of transactivators that modulate their expression. More recently, changes in physiological niches have been 
shown to affect the expression of viral genes. For many viruses, differences in oxygen tension between hypoxia and 
normoxia alter gene expression or function. Oxygen tension also affects many mammalian transactivators including 
AP-1, NFkB, and p53 by affecting the reduced state of critical cysteines in these proteins. We have recently determined 
that an essential cys-x-x-cys motif in the EBNA1 transactivator of Epstein-Barr virus is redox-regulated, such that 
transactivation is favoured under reducing conditions. The crucial Tat transactivator of human immunodeficiency virus 
(HIV) has an essential cysteine-rich region, and is also regulated by redox. Contrary to EBNA1, it is reported that Tat's 
activity is increased by oxidative stress. Here we have compared the effects of hypoxia, oxidative stress, and cellular 
redox modulators on EBNA1 and Tat.
Results: Our results indicate that unlike EBNA1, Tat is less active during hypoxia. Agents that generate hydroxyl and 
superoxide radicals reduce EBNA1's activity but increase transactivation by Tat. The cellular redox modulator, APE1/Ref-
1, increases EBNA1's activity, without any effect on Tat. Conversely, thioredoxin reductase 1 (TRR1) reduces Tat's 
function without any effect on EBNA1.
Conclusions: We conclude that oxygen partial pressure and oxidative stress affects the functions of EBNA1 and Tat in a 
dramatically opposed fashion. Tat is more active during oxidative stress, whereas EBNA1's activity is compromised 
under these conditions. The two proteins respond to differing cellular redox modulators, suggesting that the oxidized 
cysteine adduct is a disulfide bond(s) in Tat, but sulfenic acid in EBNA1. The effect of oxygen partial pressure on 
transactivator function suggests that changes in redox may underlie differences in virus-infected cells dependent upon 
the physiological niches they traffic to.
Background
The human body contains multiple niches that vary
greatly in oxygen tension. For example, lymph nodes have
oxygen partial pressure (pO2) ranging from 10-20 Torr
(1-2.5% O2) [1-3]. In contrast, peripheral blood has an
average level of 10-12% oxygen [ibid, [4]]. It is known that
the activity of many mammalian transactivators is sensi-
tive to changes in oxygen tension, leading to niche-spe-
cific gene expression patterns [5-9]. For years it has been
noted that oxidative conditions alter gene expression in
many pathogens [10-15]. Furthermore, oxygen tension is
known to affect the activity of many viral proteins,
including transactivators, thus changing the outcome of
viral infection [16-18].
One such virus that displays this characteristic is the
lymphotropic human herpesvirus, Epstein-Barr virus
(EBV). EBV is latent in B-cells that exist in the peripheral
circulation as non-dividing memory B-cells; within
lymph nodes EBV-infected cells become proliferating
blasts that secrete antibody [19,20]. These two dramati-
cally distinct cellular phenotypes result from two differ-
ent viral gene expression patterns during latency [ibid].
Recent results indicate that the EBV transactivator,
Epstein-Barr nuclear antigen 1 (EBNA1), is regulated by
oxygen tension [18]. Under hypoxic or reducing condi-
tions, EBNA1 is active as a transactivator and drives viral
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gene expression required for cell proliferation. For
EBNA1, the redox state of a pair of cysteines in a con-
served cys-x-x-cys motif governs its ability to transacti-
vate [ibid].
Similar to EBNA1, the HIV-1 Tat protein contains a
redox-sensitive cysteine-rich region with multiple cys-x-
x-cys motifs that is essential for Tat's ability to transacti-
vate [21-24]. Although it was initially believed that Tat's
cysteine-rich region was used to coordinate zinc [25,26],
it is now known that intramolecular disulfide bonds
between the cysteine sulfhydryl groups are essential for
transactivation, whereas zinc coordination is not [27-29].
Reiterating the importance of these disulfide bonds,
recent reports indicate that oxidative conditions increase
Tat's capacity to transactivate [24], whereas hypoxia
reduces transactivation [30].
Currently, there are two known mechanisms by which
oxygen tension is sensed by cysteine. High intracellular
oxygen tension results in disulfide bond formation
between neighbouring cysteine sulfhydryl groups. Alter-
natively, sulfhydryl groups can be oxidized to sulfenic
acid. While both changes can be reversed under condi-
tions of low oxygen tension, agents that reduce disulfide
bonds cannot reduce sulfenic acid to sulfhydryl [31].
In this report, we have examined the effects of oxygen
tension and oxidative stress on EBNA1 and Tat. Our
results indicate that changes in redox have opposing
effects on these two viral transactivators: EBNA1 is more
active under reducing conditions, whereas Tat is more
active under oxidative conditions. There is also a dichot-
omy in the cellular redox modulators that affect the func-
tion of EBNA1 and Tat. A redox modulator that reduces
sulfenic acid to sulfhydryl increases EBNA1's activity, but
has no effect on Tat. Conversely, modulators that reduce
disulfide bonds decrease transactivation by Tat, but have
no effect on EBNA1. We discuss the significance of our
findings in the context of EBNA1's and Tat's roles during
EBV and HIV associated pathogenesis.
Methods
Effector Plasmids
AGP441, used to express a C-terminally 3xFLAG epitope
EBNA1, was made by adding a 3xFLAG epitope tag to the
C-terminus of EBNA1 in plasmid 1553 [32]. The EBNA1-
derivative used here contains an internal deletion in the
gly-gly-ala repeat but transactivates as well as wild-type
[32] AGP535, used to express a C-terminally 3xFLAG
tagged HIV-1 Tat, was constructed by replacing the
EBNA1 ORF in AGP441 with the Tat sequence from the
prototypic HXB2 clone of HIV-1. In AGP441 and
AGP535, epitope tagged EBNA1 and Tat are expressed
from the CMV immediate early promoter. pcDNA3.1, the
empty parent expression plasmid, was used for control
transfections. AGP494 and AGP559 were used to express
APE1/Ref-1 and thioredoxin reductase-1. Plasmid 2145,
which expresses EGFP under the control of the CMV
immediate early promoter, was used to correct for trans-
fection efficiency [33].
Reporter Plasmids
The EBNA1 reporter plasmid, AGP95, has been
described previously [33]. It contains 20 EBNA1-binding
sites, termed the family of repeats (FR), placed 5' to a
minimal HSV-1 TK promoter (TKp) [34] luciferase
reporter cassette. AGP546, the Tat reporter plasmid was
constructed by excising FR from AGP95, and then insert-
ing the TAR element from HIV-1 (LAV) between TKp
and the luciferase gene. Similar to Tat-responsive, TAR-
containing reporters described before [35], in AGP546
the first nucleotide transcribed is the first nucleotide of
U5. Plasmid AGP47, TKp-luciferase, was used in some
experiments as a control plasmid. This plasmid lacks
EBNA1 binding sites, and there is no TAR element in the
luciferase transcript from TKp.
Cell Culture and Transfections
The human cell epithelial cell-line, C33a, was propagated
in DMEM:F12 (1:1) supplemented with 5% bovine calf
serum. Cells were maintained in a 5% CO2 incubator
under normoxic (20% O2), or hypoxic (4% O2) conditions.
Cells were transfected as described previously. Pharma-
cologic agents including menadione, paraquot dichloride,
sodium selenite, beta-mercaptoethanol, glutathione, and
N,N,N',N'-tetrakis (2 pyridylmethyl) ethylenediamine
(TPEN) were purchased from Sigma (St. Louis, MO), and
added 6 hours post-transfection, and cells were harvested
18-20 hours post-addition. Control cells were treated to
the vehicle for the specific pharmacologic agent being
tested. Transfections were normalized using the GFP
expression plasmid, 2145 by FACS profiling a fraction of
each transfection to determine the fraction of live-trans-
fected cells (GFP-positive cells that did not stain with
propidium iodide). This analysis was used to correct for
differences in transfection efficiency or cell survival post-
transfection as described previously [18,33,36,37].
Hypoxia Conditions
Cells used in hypoxia experiments were grown in a sealed
modular incubation chamber (Billups-Rothenberg, Inc,
Del Mar, CA) placed at 37°C. The chamber was flushed
with 4% O2 (AirGas, Theodore, AL) for five minutes prior
to sealing. Chambers were re-equilibrated every 12
hours. When necessary, media changes were performed
using media previously equilibrated in a 4% O2 atmo-
sphere.Washington et al. Virology Journal 2010, 7:93
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Luciferase Reporter Assays
For Tat assays, 0.3 μg of the reporter AGP546 (TKp-TAR-
luciferase) was co-transfected with 10 μg of the Tat-
expression plasmid AGP535, and 0.5 μg of the CMV-GFP
plasmid. For EBNA1 assays, 0.3 μg of the reporter AGP95
(FR-TKp-luciferase) was co-transfected with 2 μg of the
EBNA1 expression plasmid, AGP441, and the CMV-GFP
plasmid as described above. Plasmid AGP47, TKp-
luciferase, was used in some experiments as a control
plasmid. Cells were harvested 24 hours post-transfection,
and analyzed to determine the percent of live-transfected
cells, prior to luciferase assays performed as described
previously [18,33,36,37].
Indirect Immunofluorescence Microscopy and Image 
Deconvolution
Cells transfected with the TAT-3xFLAG or EBNA1-
3 x F L A G  e x p r e s s i o n  p l a s m i d s  w e r e  p l a t e d  o n  T y p e  1
cover slips and processed for immunofluorescence as
described previously [18,36,37]. The M2 anti-FLAG
mouse monoclonal Ab (Sigma) was used as the primary
antibody, and AlexaFluor 488 tagged anti-mouse Ab was
used as the secondary Ab. Hoechst 33342 was used as the
counter-stain to visualize nuclei. Images were obtained
using an inverted Zeiss AxioVision AX10 microscope at
63X using an AxioCam MRm camera. Z-stacks contain-
ing fifteen 200 nm optical sections were deconvolved
using a constrained iterative Fourier transform.
Immunoblotting
Immunoblots were performed as described previously
using the M2 anti-FLAG mouse mAb (1:1000 dilution) as
the primary antibody [38], and horseradish peroxidase
conjugated rabbit anti-mouse secondary antibody. Anti-
actin primary Abs, ab8226 (Abcam) or A8592 (Sigma)
were used to detect beta-actin for as a loading control.
Blots were visualized by chemiluminescence as described
previously [36-38].
Results
Choice of reporter cell-line, and construction of a Tat 
reporter plasmid
Our experiments comparing the effects of redox on
EBNA1 and Tat were performed in C33a cells for the fol-
lowing reasons. Multiple studies indicate that EBNA1
efficiently transactivates an FR-dependent reporter in
C33a cells [18,33,37,39]. In addition, we have character-
ized metal ion requirements and some effects of oxidative
stress on EBNA1's ability to transactivate in these cells
[18]. Tat is known to transactivate an HIV-LTR luciferase
reporter in multiple cell-lines including epithelial lines
such as 293 and the Hela derivative TZM-bl. Therefore,
after confirming that Tat transactivated an HIV-LTR
reporter in C33a cells (data not shown), we chose C33a
cells for this study. Studying both transactivators in the
same cell-line has permitted comparing them without the
interpretational complications caused by using two dif-
ferent cell-lines.
Both reporter plasmids used the minimal TK promoter
(TKp), rather than native viral promoters because viral
promoters that respond to EBNA1 or Tat contain binding
sites for cellular redox-responsive transcription factors
[5,7,8,40,41]. Previous studies [18], as well as results
reported here, indicate that basal transcription from TKp
is not redox-sensitive. For EBNA1, we have used the
reporter FR-TKp-luciferase, in which a cluster of 20
EBNA1 binding sites from the EBV genome is placed 5' to
a TKp-luciferase reporter cassette [33,39]. We con-
structed an analogous reporter for Tat by inserting the
HIV-1 TAR RNA element between TKp and the
luciferase gene. This reporter, TKp-TAR-luciferase, con-
tains 77 nucleotides of HIV-1 sequence from the LAV
strain of HIV-1 between the TKp and luciferase [35]. The
first nucleotide transcribed in TKp-TAR-luciferase is pre-
dicted to be the first nucleotide in the HIV-1 RNA
genome.
Schematic representations of epitope-tagged EBNA1
and Tat are shown in Figure 1A, emphasizing the
domains of these two proteins that are required to bind
their cognate recognition sites on DNA or RNA, and the
domains that are redox-responsive. EBNA1's DNA-bind-
ing domain (DBD) (a.a. 451-641) is used to bind the 20
EBNA1-binding sites in FR [39]. The UR1 domain of
EBNA1 (a.a. 65-89) contains a redox-regulated cys-x-x-
cys motif that is essential for transactivation [18]. Tat uses
its basic region (BR) (a.a. 38-59) to bind TAR, and con-
tains a redox-regulated cysteine-rich region (CRR) (a.a.
22-37) essential for transactivation [23,28]. The expres-
sion of these epitope tagged proteins is shown in Figure
1B; neither EBNA1 nor Tat was observed to be exten-
sively degraded within the time-course of these experi-
ments. Indirect immunofluorescence indicated that
epitope-tagged EBNA1 and Tat had sub-cellular localiza-
tions similar to untagged EBNA1 and Tat (Figure 1C). Tat
was observed to be both nuclear and cytoplasmic,
whereas EBNA1 was predominantly nuclear. The
epitope-tagged versions of EBNA1 and Tat are referred to
as EBNA1 and Tat in this report.
The reporter plasmids used to assay transactivation by
EBNA1 and Tat are schematically depicted in Figure 1D.
As described earlier, both plasmids contain a TKp-
luciferase reporter cassette in either an EBNA1 (AGP95)
or Tat (AGP546) responsive context. EBNA1 transacti-
vated FR-TKp-luciferase approximately 55-fold over
pcDNA3, used as a control effector plasmid, and Tat
transactivated TKp-TAR-luciferase approximately 9-fold
over pcDNA3 (Figure 1E). Both EBNA1 and Tat can coor-
dinate zinc. However, while EBNA1 needs zinc coordina-Washington et al. Virology Journal 2010, 7:93
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Figure 1 Characterization of epitope-tagged EBNA1 and Tat. (A) Diagrams of epitope-tagged EBNA1 and Tat. EBNA1 is 641 a.a. long and binds 20 
sites in the EBV FR through its DNA binding domain (DBD). EBNA1's UR1 domain, essential for transactivation, contains a redox-regulated cys-x-x-cys 
motif. Tat is 87 a.a. long and binds HIV-1 TAR RNA through its basic region (BR) Tat's redox-regulated cysteine-rich (CRR) is required for transactivation. 
(B) Epitope-tagged EBNA1 and Tat, expressed in C33a cells, were visualized as described in the materials and methods. (C) Indirect immunofluores-
cence indicates EBNA1 is primarily nuclear, while Tat is nuclear and cytoplasmic. Proteins were visualized as described in the materials and methods. 
Bars indicate a scale of 10 μM. (D) Diagram of the transcription reporter plasmids. The minimal TK promoter (TKp) in both reporters has -1 to -80 of the 
HSV-1 TK promoter. The Tat reporter, TKp-TAR-luciferase, contains the HIV-1 TAR between the promoter and the luciferase gene. The EBNA1 reporter, 
FR-TKp-luciferase, contains the EBV FR 5' to the TKp. The HSV-1 TK polyadenylation signal (TKpA) was used for polyadenylation. (E) 24 hours post-trans-
fection, epitope-tagged EBNA1 transactivates FR-TKp-luciferase 55-fold over the control (pcDNA3) (left-hand scale). Epitope-tagged Tat transactivates 
TKp-TAR-luciferase 10-fold over pcDNA3 (right-hand scale). (F) Exposure to 1 μM TPEN, a zinc chelator, reduced transactivation of FR-TKp-luciferase by 
EBNA1 to 50% of control, as observed for native EBNA1. TPEN did not alter transactivation by Tat. The asterisk indicates statistical significance by the 
Wilcoxon rank-sum test (p < 0.05) over control conditions.Washington et al. Virology Journal 2010, 7:93
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tion to transactivate [18], Tat does not [28]. To confirm
that the metal-ion (zinc) requirements of the epitope-
tagged proteins were unchanged, transfected cells were
exposed to TPEN, a chelator with high specificity for
Zn2+ and Fe2+. TPEN treatment began six hours post-
transfection and continued for an additional 18 hours
prior to analysis. Treatment with 1 μM TPEN reduced
EBNA1's transactivation of FR-TKp-luciferase to 50% of
control conditions (Figure 1F), but had no statistically sig-
nificant effect on transactivation of TKp-TAR-luciferase
by Tat, reproducing prior observations made with the
native proteins [18,28]. This experiment also confirms
that TPEN does not have a non-specific effect on tran-
scription, nor does it directly affect the basal transcrip-
tion machinery active at the minimal TK promoter
(Additional File 1A).
Hypoxia alters transactivation by Tat and EBNA1
EBNA1 and Tat contain redox-sensitive cysteines that are
essential for transactivation [18,28], and oxidative stress
is known to alter the ability of these proteins to transacti-
vate [18,24]. Oxidation modifies cysteines in two distinct
ways: 1) by oxidizing adjacent sulfhydryl groups to form
inter- or intra-molecular disulfide bods, and 2) by oxidiz-
ing cysteines to sulfenic acid and further oxidized deriva-
tives [31]. Hypoxic conditions decrease the generation of
intracellular reactive oxygen species and therefore favour
the presence of sulfhydryl groups over oxidized deriva-
tives [42]. Therefore, we examined if hypoxia (4% O2)
altered transactivation by EBNA1 or Tat, shown in Figure
2. Consistent with previous reports (Figure 2A), for
EBNA1, hypoxia significantly increased transactivation to
130% over normoxia transactivation, defined as control
conditions, within 24 hours of exposure to 4% O2. In con-
trast, 4% O2 significantly reduced Tat's capacity to trans-
activate to 25% of normoxic conditions (Figure 2A),
consistent with recently published reports indicating that
hypoxia reduces Tat's ability to transactivate whereas
depletion of cellular redox modulators increases transac-
tivation [24,30]. The changes in transactivation induced
by hypoxic conditions did not result from an altered
expression of EBNA1 or Tat during hypoxia (Figure 2B).
In addition, this experiment indicates that the augmenta-
tive effect of hypoxia on EBNA1 does not result from
direct changes to the basal transcription machinery func-
tional at the minimal HSV-1 TK promoter. To confirm
that hypoxia does not directly affect the basal transcrip-
tion machinery active at the TK promoter, expression
from reporter AGP47 (TKp-luciferase) was examined
under hypoxia and normoxia. No significant difference in
reporter expression was observed confirming that
hypoxia does not affect basal transcription from TKp
(Additional File 1B).
Next, we tested whether agents that increase intracellu-
lar oxidative stress altered transactivation by EBNA1 and
Tat in a manner opposite to the effect of hypoxia.
Differing effects of the oxidizing agents menadione and 
paraquot on Tat and EBNA1
EBV and HIV-1 infected cells reside in anatomical niches
that differ in oxygen partial pressure (pO2). EBV-infected
Figure 2 Hypoxia increases transactivation by EBNA1 and reduc-
es transactivation by Tat. (A) Transfected C33a cells were split 6 
hours post-transfection into aliquots incubated under normoxia (N) or 
hypoxia (H). Luciferase activity was assayed at 24 hours post-transfec-
tion. Transactivation is expressed as a percent of transactivation ob-
served under normoxic (control) conditions. Hypoxia increased 
transactivation by EBNA1 increased to 125% of normoxic conditions, 
but decreased transactivation by Tat to 25% of normoxic conditions. 
(B) Immunoblots indicate that hypoxia did not alter expression of Tat 
or EBNA1. β-actin was used as a loading control. Asterisks indicate sta-
tistical significance by the Wilcoxon rank-sum test (p < 0.05) when 
comparing results obtained under hypoxia against normoxia.Washington et al. Virology Journal 2010, 7:93
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cells proliferate in niches with low pO2  (≤ 4% O2)
[19,43,44], indicating high levels of viral gene expression
i n  s u c h  n i c h e s.  O n  t h e  o t h e r  h a n d ,  i t  i s  r e po rt ed  t h a t
HIV-1 RNA levels are generally lower in anoxic niches
such as the brain or CSF, when compared to plasma viral
load from the same patient [45,46]. Conversely in periph-
eral circulation (≥ 10% O2) [43,44], EBV-infected cells
reside as quiescent memory B-cells, whereas higher levels
of HIV RNA is detected in plasma [45,46].
pO2-dependent intracellular Fenton reactions generate
hydroxyl and superoxide radicals and thereby create a
continuous flux of intracellular oxidative stress in
response to the extracellular pO2 [42]. Normoxia (21%
O2) increases the rate of radical generation over the
hypoxic conditions that are present in most tissues. Cells
that are explanted compensate for the increased oxidative
stress by over-expressing proteins that scavenge radicals
or reduce oxidized adducts [47,48]. It is believed cell-lines
that cell-lines are more resistant to pO2-induced oxidative
stress than primary cells for the same reason [ibid].
Therefore, low levels of chemical oxidants can be used
under normoxia to increase radical generation and
thereby circumvent the difficulty in inducing oxidative
stress by solely increasing pO2 [49]. Menadione and para-
quot are most frequently used to increase intracellular
hydroxyl and superoxide radicals [50-52], and were there-
fore selected as the most suitable oxidizing agents for this
study.
For the experiments shown in Figure 3, C33a cells
transfected with effector and reporter plasmids were split
six hours post-transfection into aliquots that were
exposed to the indicated ranges of menadione (Figure 3A)
and paraquot (Figure 3B) for 18 hours. At this time,
reporter expression was assayed and is indicated as per-
cent of reporter expression observed in the absence of
menadione or paraquot (control conditions). As observed
previously [18], menadione (Figure 3A) decreased trans-
activation by EBNA1 in a dose-dependent manner with
significant decreases at concentrations at or greater than
1.4 μM. EBNA1's capacity to transactivate the FR-TKp-
luciferase reporter was reduced to 50% by 2 μM menadi-
one. In striking contrast, menadione caused a dose-
dependent increase in transactivation of TKp-TAR-
luciferase by Tat, with significant increases at 1.4 μM
menadione and higher. At a concentration of 2 μM mena-
dione, Tat-dependent reporter expression increased to
175% of control. Similar to menadione, paraquot treat-
ment (Figure 3B) reduced transactivation by EBNA1
while increasing transactivation by Tat. For example, 400
μM paraquat increased Tat's activity to 150% of control,
but reduced EBNA1's activity to 50% of control (Figure
3B). Changes in transactivation caused by menadione and
paraquot did not result from altered expression of
EBNA1 or Tat. (Figure 3C, 3D). Oxidative stress also did
not affect basal transcription from the TKp (Additional
Figure 1C).
Beta-mercaptoethanol selectively diminishes 
transactivation by Tat
Oxidation of sulhydryls (-SH) results in either disulfide
bond formation (-S-S-) or the progressive formation of
sulfenic (-SO), sulfinic (-SO2), and sulfonic acid (-SO3)
[31]. Chemical reductants such as beta-mercaptoethanol
or dithiothreitol can reduce disulfide bonds, but have no
effect on the other oxidized derivatives of sulhydryl.
Therefore, they can be used to distinguish between the
two types of adducts that can result from oxidative stress.
To evaluate the effect of reducing agents, cells trans-
fected with effector and reporter plasmids were split six
hours post-transfection, and aliquots were exposed to a
titration of beta-mercaptoethanol (Figure 4A) and dithio-
threitol. When assayed 18 hours later concentrations of
beta-mercaptoethanol of 30 μM and higher significantly
diminished Tat's capacity to transactivate, but had no sig-
nificant effect on EBNA1. No effect on either protein was
observed at 10 μM, and a variable effect on Tat was
observed at 20 μM. Between 30-300 μM, beta-mercapto-
ethanol had no effect on transcription from the minimal
TK promoter (Additional File 1D). Deleterious effects on
cells were observed at concentrations greater than 300
μM (data not shown).
At 300 μM and less, beta-mercaptoethanol had no
effect on cell proliferation or viability. In addition, no
effect on the expression of Tat or EBNA1 was observed
(Figure 4B). Attempts to confirm these results using
dithiothreitol were thwarted by its toxicity on cells. In a
single experiment, glutathione at a concentration of 8
μM, reduced transactivation by Tat to 40% of control,
without affecting transactivation by EBNA1 (data not
shown.
We further dissected these results by examining the
effect of over-expressing two common cellular redox
modulators, namely AP-endonuclease 1 (APE1/Ref-1)
and thioredoxin reductase 1 (TRR1).
Over-expression of APE1/Ref-1 selectively augments 
transactivation by EBNA1
The DNA repair enzyme APE1 (also known as Ref-1) has
two functions. It cleaves DNA at apurinic/apyrimidinic
sites, and regulates the function of multiple transactiva-
tors whose activities are redox-dependent [5-9]. APE1/
Ref-1 reduces sulfenic acid back to sulfhydryl [31],
although it is unknown whether it can also reduce a disul-
fide bond. C33a cells were co-transfected with reporter
and effector plasmids and variable amounts of an APE1/
Ref-1 expression plasmid. Reporter activity was assayed
24 hours post-transfection. As shown in Figure 5A,Washington et al. Virology Journal 2010, 7:93
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APE1/Ref-1 significantly augments EBNA1's ability to
transactivate to as much as ~200% of control. Transacti-
vation was augmented as a function of increasing the lev-
els of a co-transfected APE1/Ref-1 expression plasmid.
This observation, made with epitope-tagged EBNA1 is
similar to our previous observations with untagged
EBNA1 [18]. In contrast to EBNA1, APE1/Ref-1 had no
effect on transactivation by Tat (Figure 5A). APE1/Ref-1
did not augment EBNA1's ability to transactivate by
increasing EBNA1 expression (Figure 5B).
Selenium and over-expression of thioredoxin reductase 1 
(TRR1) selectively reduce transactivation by Tat
Tat protein reduced in vitro is transactivation impaired
when electroporated into cells [28]. Consistent with this
observation, recent reports indicate that RNA-interfer-
ence mediated depletion of increases Tat's capacity to
transactivate in the monocytic cell-line U937, and Tat
binds TRR1 in vitro [24]. TRR1 is a cytoplasmic seleno-
enzyme that recycles thioredoxin by reducing disulfide
bonds [53]. In addition, TRR1 also directly reduces disul-
fide bonds in a number of substrate proteins [24,53]. The
HIV-1 LTR contains binding sites for multiple redox-sen-
sitive transcription factors including NFkB and Sp1. The
effect of TRR1 on Tat's ability to transactivate the HIV-1
LTR was performed using an LTR derivative in which the
NFkB sites were deleted [24]. However this LTR-based
Tat reporter still contains intact Sp1 sites, a transcription
factor that is redox regulated by thioredoxin and by TRR1
[54].
The minimal TK promoter used in the TKp-TAR-
luciferase reporter described here lacks recognition sites
for Sp1 or any other major redox-regulated transcription
factor. Therefore, we tested whether activating TRR1 by
the addition of selenium (Figure 6A), or over-expression
of TRR1 (Figure 6B), would decrease Tat's ability to trans-
activate. For the data shown in Figure 6A, C33a cells
transfected with effector and reporter plasmids were split
Figure 3 Oxidative stress induced by menadione and paraquot decrease transactivation by EBNA1, but increase transactivation by Tat. (A) 
Transfected C33a cells were split 6 hours post-transfection into aliquots and exposed to the indicated concentrations of menadione, or paraquot (B) 
for an additional 18 hours, prior to reporter analysis. The inset legend indicates the columns corresponding to each effector/reporter combination. 
Control cells were vehicle treated. Transactivation is expressed as a percent of transactivation observed in the control cells. Immunoblots indicate that 
neither menadione (C), nor paraquot (D) altered the expression of EBNA1 or Tat. β-actin was used as a loading control. Asterisks indicate statistical 
significance by the Wilcoxon rank-sum test (p < 0.05) for treated samples compared to vehicle-treated controls.Washington et al. Virology Journal 2010, 7:93
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six hours post-transfection, and aliquots exposed to
increasing concentrations of selenium (0.01 - 0.1 μM). As
shown in Figure 6A, the addition of 0.01 μM and higher
concentration of selenium significantly decreased Tat's
capacity to transactivate. At 0.1 μM, Tat transactivated
TKp-TAR-luciferase at 55% the level observed in the
absence of selenium. Selenium did not affect EBNA1's
ability to transactivate FR-TKp-luciferase. Next, the effect
of TRR1 over-expression was tested (Figure 6B). Over-
expressed TRR1 negatively affected Tat's capacity to
transactivate significantly, even in the absence of addi-
tional added selenium (Figure 6B), such that co-transfec-
tion of 1 μg of a TRR1 expression plasmid reduced Tat's
capacity to transactivate to 45% of control. No further
effect was observed with higher amounts of the co-trans-
f e c t e d  T R R 1  e x p r e s s i o n  p l a s m i d .  O v e r - e x p r e s s i o n  o f
TRR1 had no effect on EBNA1's ability to transactivate
(data not shown). While we were initially surprised that
Figure 4 Beta-mercaptoethanol reduces transactivation by Tat, but has no effect on transactivation by EBNA1. (A) Transfected C33a cells 
were split 6 hours post-transfection into aliquots and exposed to the indicated concentrations of beta-mercaptoethanol (β-ME) for an additional 18 
hours, prior to reporter analysis. The inset legend indicates the columns corresponding to each effector/reporter combination. Control cells were ve-
hicle treated. Transactivation is expressed as a percent of transactivation in the absence of beta-mercaptoethanol (control conditions). (B) Immunob-
lots indicate that beta-mercaptoethanol did not affect expression of EBNA1 or Tat. β-actin was used as a loading control. Asterisks indicate statistical 
significance by the Wilcoxon rank-sum test (p < 0.05) for treated samples compared to vehicle-treated controls.
Figure 5 APE1/Ref-1 increases transactivation by EBNA1, but does not alter transactivation by Tat. (A) C33a cells were co-transfected with re-
porter and effector plasmids, and the indicated amount of an APE1/Ref-1 expression plasmid. The backbone expression plasmid, pcDNA3.1 was used 
to normalize the amount of DNA used in each transfection. Reporter activity was measured 24 hours post-transfection. Transactivation is expressed 
as a percent of transactivation observed in the absence of co-transfected pAPE1 (control conditions). The inset legend indicates the columns corre-
sponding to each effector/reporter combination. (B) Immunoblots indicate that expression of APE1/Ref-1 did not alter expression of EBNA1 or Tat. β-
actin was used as a loading control. Asterisks indicate statistical significance by the Wilcoxon rank-sum test (p < 0.05) for APE1/Ref-1 transfected cells 
compared to control cells where pcDNA3.1 was co-transfected with the effector and reporter plasmids.Washington et al. Virology Journal 2010, 7:93
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Figure 6 Selenium and thioredoxin reductase 1 (TRR1) reduce transactivation by Tat. (A) Transfected cells were split 6 hours post-transfection 
into aliquots and exposed to the indicated concentrations of sodium selenite for 18 hours before analysis. The inset legend indicates the columns 
corresponding to each effector/reporter combination. Asterisks indicate statistical significance by the Wilcoxon rank-sum test (p < 0.05) for selenium 
treated samples compared to vehicle treated samples (B) C33a cells were co-transfected with Tat expression and reporter plasmids and indicated 
amounts of a TRR1 expression plasmid. pcDNA3.1 was used to normalize the amount of DNA used per transfection. Transfections was split six hours 
post-transfection, and half the transfected cells were exposed to 0.03 μM sodium selenite for an additional 18 hours before analysis. Transactivation 
is expressed as a percent of transactivation observed in the absence of co-transfected pTRR1 or added sodium selenite (control conditions). The inset 
legend indicates the columns corresponding to co-transfected pTRR1 alone, or co-transfected pTRR1 with sodium selenite addition. Asterisks indicate 
statistical significance by the Wilcoxon rank-sum test (p < 0.05) for TRR1 transfected cells compared to controls in which pcDNA3.1 was co-transfected 
with reporter and effector plasmids, and cells were not exposed to sodium selenite. (C) Immunoblot analysis indicates that treatment with sodium 
selenite does not alter the expression of EBNA1 or Tat. In addition, co-transfected pTRR1 does not affect the expression of Tat in the presence of ab-
sence of 0.03 μM sodium selenite added to the media. β-actin was used as a loading control.Washington et al. Virology Journal 2010, 7:93
http://www.virologyj.com/content/7/1/93
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over-expression of TRR1 decreased Tat's capacity to
transactivate even in the absence of added selenium, it is
possible that the over-expressed TRR1 uses the pre-exist-
ing intracellular selenium pool to form the active enzyme.
Alternatively, it has been reported that TRR1 reduces
many disulfide bonds in the absence of selenium [53]. We
also tested whether the combination of over-expressed
TRR1 and selenium addition would further decrease Tat's
capacity to transactivate in cells that over-express TRR1.
As shown in Figure 6B; addition of 0.03 μM selenium
reduced transactivation by Tat to 25% in cells co-trans-
fected with 1 μg of the TRR1 expression plasmid. Addi-
tion of selenium had no effect on the expression of
EBNA1 or Tat, and over-expression of TRR1 also had no
effect on Tat expression (Figure 6C), confirming that the
decrease in transactivation did not result from a decrease
in Tat levels.
Because TRR1 reduces oxidized thioredoxin that acts
to reduce disulfide bonds, we also tested whether over-
expression of thioredoxin affected Tat's activity. In multi-
ple experiments, thioredoxin did not affect transactiva-
tion by Tat (data not shown), thus confirming the
observation that TRR1 directly interacts with Tat to affect
transactivation [24].
Discussion
Virus infection results in different outcomes for HIV-1
and EBV. Infection by HIV-1 results in the depletion of a
T-cell subset, whereas EBV immortalizes naive B-cells.
EBV-immortalized cells proliferate in lymph nodes, a rel-
atively anoxic niche within the body, and EBV-positive
lymphomas also proliferate at anoxic sites [19,43,44]. In
peripheral circulation, EBV-immortalized cells are found
as quiescent memory-B cells [44]. The effect of pO2 alter-
ations is less clear for HIV-1 pathogenesis. In general,
higher levels of HIV-1 RNA are detected in peripheral
circulation, while lower levels are observed in anoxic
niches [45,46].
It is likely that numerous physiological and cellular con-
ditions result in differences observed for these viruses in
differing physiological niches. On the basis of the results
from this study, we speculate that redox-dependent func-
tion of two critical viral transactivators may underlie
niche-dependent differing outcomes of infection.
EBNA1 transactivates the expression of a subset of EBV
genes required to drive the proliferation of EBV-infected
cells. Therefore, hypoxic/anoxic conditions that increase
transactivation of these genes by EBNA1 may contribute
to the proliferative phenotype displayed by EBV-infected
cells in lymph nodes and other anoxic sites.
In the absence of Tat, HIV-1 mRNA and genomic tran-
scripts are prematurely terminated. Our results, and
those of others, indicate that oxidizing conditions
increase the expression of a TAR-dependent reporter in
the presence of Tat [24]. In addition, our results indicate
that hypoxia decreases the activity of Tat, similar to other
recent observations [30]. Reduction of Tat with chemical
agents also decreases its transactivation capacity [28].
Together these observations contrast with earlier obser-
vations that anoxic conditions increased HIV-1 RNA
expression [55]. This difference could potentially arise
from the activation of cellular transactivators under
hypoxic conditions or cellular differences. Superficially,
our results also contrast with those reported recently on
the effect of bacterially expressed, exogenously added Tat
for HIV-1 infection of primary T-cells [4]. In this study,
under hypoxic conditions, exogenously provided Tat
primed T-cells for HIV-1 infection. The reason for this
difference is unknown; it may be pertinent that we have
examined the activity of Tat on a TAR-dependent
reporter, but the mechanism by which exogenously added
Tat primes naive T-cells for infection by HIV-1 is
unknown. In this context, we note that administration of
the reducing agent, N-acetyl cysteine, inhibits HIV-1
expression in a chronically infected cell model [56,57]. It
is possible that this decreased expression results by
reducing the capacity of Tat to transactivate.
Finally, at a molecular level, our results can be inter-
preted to indicate that oxidative stress modifies sulfhy-
dryl groups on EBNA1 and Tat differently. Consistent
with results reported previously [24], the effects of beta-
mercaptoethanol and over-expression of TRR1 suggests
that oxidized cysteines in Tat exist as disulfide bonds. In
contrast, neither beta-mercaptoethanol nor TRR1 have
any effect on EBNA1, suggesting the EBNA1 oxidation
does not result in disulfides. This conclusion is supported
by the observation that APE1/Ref-1, which reduces
sulfenic acid to sulfhydryl, augments transactivation by
EBNA1.
In summary, our studies have unexpectedly revealed
dramatically different effects of oxidative stress on these
two viral transactivators. This difference may reflect the
physiological sites that cells infected by EBV and HIV-1
traffic to. The differential effect of oxidative stress has
implications for potential therapeutic interventions that
target oxidative stress in patients co-infected with both
viruses.
Conclusions
The activity of EBNA1, a critical EBV transactivator, and
Tat, a critical HIV-1 transactivator, are modulated by
redox. Oxygen tension and oxidative stress have strik-
ingly opposite effects on the capacity of these proteins to
transactivate. Hypoxia increases transactivation by
EBNA1, while decreasing Tat transactivation. Conversely,
reactive oxygen species generated by menadione and
paraquot reduce transactivation by EBNA1 but increase
Tat function. The cellular redox modulators APE1/Ref-1Washington et al. Virology Journal 2010, 7:93
http://www.virologyj.com/content/7/1/93
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and TRR1 have transactivator-specific effects. APE1/Ref-
1 augments EBNA1's capacity to transactivate with no
effect on Tat. On the other hand, TRR1 reduces Tat's
capacity to transactivate without affecting EBNA1. This
data permits us to propose that the redox-dependent
functions of EBNA1 and Tat may underlie the behavior of
EBV and HIV infected cells within physiological niches
that differ in oxygen tension.
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